ESSA Pharma Inc

자세한 내용은 ESSA Pharma Inc 회사

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

회사 정보

종목 코드 EPIX

회사 이름ESSA Pharma Inc

상장일Feb 22, 2021

CEODr. David Ross Parkinson, M.D.

직원 수35

유형Ordinary Share

회계 연도 종료Feb 22

주소999 West Broadway, Suite 720

도시VANCOUVER

증권 거래소NASDAQ Capital Market Consolidated

국가Canada

우편 번호V5Z 1K5

전화17783310962

웹사이트https://www.essapharma.com/

종목 코드 EPIX

상장일Feb 22, 2021

CEODr. David Ross Parkinson, M.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Richard M. Glickman, LL.D.

Non-Executive Independent Chairman of the Board

51.70K

-14.06%

Mr. David Sidney Wood, CPA

Chief Financial Officer

33.59K

+0.75%

Mr. Scott Requadt

Independent Director

30.00K

--

Mr. Peter Virsik

Chief Operating Officer, Executive Vice President

7.78K

--

Dr. Alessandra Cesano, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

5.12K

--

Ms. Marella Thorell

Independent Director

2.88K

--

Mr. Franklin M. Berger

Independent Director

--

Mr. Sanford (Sandy) Zweifach, CPA

Independent Director

--

Dr. David Ross Parkinson, M.D.

President, Chief Executive Officer, Director

--

Mr. Alex Martin

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Richard M. Glickman, LL.D.

Non-Executive Independent Chairman of the Board

51.70K

-14.06%

Mr. David Sidney Wood, CPA

Chief Financial Officer

33.59K

+0.75%

Mr. Scott Requadt

Independent Director

30.00K

--

Mr. Peter Virsik

Chief Operating Officer, Executive Vice President

7.78K

--

Dr. Alessandra Cesano, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

5.12K

--

Ms. Marella Thorell

Independent Director

2.88K

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

BVF Partners L.P.

19.71%

Soleus Capital Management, L.P.

9.83%

Tang Capital Management, LLC

9.69%

BML Capital Management LLC

9.51%

Morgan Stanley & Co. LLC

9.46%

Other

41.80%

주주

비율

BVF Partners L.P.

19.71%

Soleus Capital Management, L.P.

9.83%

Tang Capital Management, LLC

9.69%

BML Capital Management LLC

9.51%

Morgan Stanley & Co. LLC

9.46%

Other

41.80%

주주 유형

주주

비율

Hedge Fund

46.19%

Investment Advisor

13.36%

Research Firm

11.99%

Corporation

3.77%

Investment Advisor/Hedge Fund

2.45%

Individual Investor

2.24%

Venture Capital

0.05%

Other

19.93%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

91

33.44M

75.34%

-17.34M

2025Q1

96

33.48M

75.44%

-17.56M

2024Q4

101

34.20M

77.05%

-15.63M

2024Q3

97

36.44M

82.10%

-7.65M

2024Q2

110

36.54M

82.36%

-10.99M

2024Q1

138

36.33M

81.91%

-11.35M

2023Q4

143

35.77M

81.03%

-12.57M

2023Q3

161

36.59M

82.99%

-18.42M

2023Q2

177

36.37M

82.51%

-21.24M

2023Q1

185

36.21M

82.14%

-19.98M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

BVF Partners L.P.

8.75M

19.71%

--

Apr 09, 2025

Soleus Capital Management, L.P.

2.26M

5.1%

--

Apr 23, 2025

Tang Capital Management, LLC

4.30M

9.69%

--

Mar 31, 2025

BML Capital Management LLC

4.22M

9.51%

--

Apr 24, 2025

Morgan Stanley & Co. LLC

4.20M

9.46%

+10.76K

+0.26%

Mar 31, 2025

Opaleye Management Inc.

2.21M

4.98%

--

Mar 31, 2025

Pfizer Inc

1.68M

3.77%

--

Mar 31, 2025

Altium Capital Management LP

1.05M

2.37%

-377.63K

-26.44%

Mar 31, 2025

Berger (Franklin Milan)

784.40K

1.77%

--

Jan 08, 2025

BofA Global Research (US)

698.27K

1.57%

-114.04K

-14.04%

Mar 31, 2025

1.880USD

ESSA Pharma Inc

1.880

개요

회사

금융